NasdaqGM:WVEPharmaceuticals
Assessing Wave Life Sciences (WVE) Valuation After Volatile Reaction To WVE-007 Phase 1 Results
Wave Life Sciences (WVE) is back in focus after six month Phase 1 data for its obesity candidate WVE-007 showed reductions in visceral and total fat, yet sparked sharp stock volatility and analyst reassessments.
See our latest analysis for Wave Life Sciences.
The six month WVE-007 update has arrived at a volatile moment for Wave Life Sciences, with a 1 day share price return of negative 49.6% at US$6.20 and a year to date share price return of negative 61.1% contrasting with a 3 year total...